: iStockAnalyst.com Symbols Feed

FDA Calendar Updates: EURX, AMGN, FOLD, ONTY, MEDX

Tue, 23 Jun 2009 00:14:00 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of over 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response lette (...)[More...]

10 Extreme Trades On Pending Clinical Trial Results

Thu, 14 May 2009 15:37:15 GMT

As a follow-up to my recent article on nine extreme FDA trades of pending new product decisions among small and micro-cap companies, I have examined the BioMedReports.com Clinical Trial Calendar database to find companies with market caps below $250M which have pending Phase 2 or 3 clinical trial results expected before the end of 2009. Below is a sample of 10 stocks meeting this criteria from the database of 111 entries included in the BioMedReports.com Clinical Trial Calendar, which is in addi (...)[More...]

Analyst Comments: EOG Resources, Charlotte Russe, VeraSun Energy, Thornburg Mortgage, Amicus Therapeutics

Thu, 31 Jul 2008 19:55:00 GMT

EOG Resources, Inc.'s (EOG) quarterly results came in better-than-expected, reflecting increased volumes and improved commodity-price realizations, partly offset by higher costs. Domestic natural gas production grew 19%, while liquids volumes rose 51% over last year. Additionally, the company raised its quarterly dividend by 12.5% to $0.135 a share. With robust growth from most of its core areas, EOG remains on track to achieve production growth of 15% this year and approximately 14% over the following two years. We maintain our Buy recommendation on EOG shares and see the stock as a core holding in the large-cap exploration and production (E&P) space. EOG is targeting 2008 production growth of approximately 15%. Driving this growth will be the company's U.S. operations, estimated to grow approximately 23% year-over-year all organic. The U.S. growth will mainly come from[More...]

Analyst Comments: Accenture, Immucor, Luminent Mortgage, ATA, AtriCure, Amicus Therapeutics, Sanderson Farms

Mon, 14 Apr 2008 14:26:56 GMT

This company beat Wall Street estimates for the second quarter by 12.28% on the back of record consulting bookings.[More...]

Analyst Comments: Amicus Therapeutics, Norfolk Southern Corporation, Baxter International, Patterson-UTI, Tower Group, Tele Norte Leste Participações, Au Optronics,

Thu, 31 Jan 2008 13:14:46 GMT

Zacks senior biotechnology analyst Grant Zeng, CFA has effected a downward revision to the price target from his earlier position but maintained his Hold rating to Amicus Therapeutics, Inc. (FOLD). We excerpted the following details:[More...]

Analyst Comments: BASF Aktiengesellschaft, Allscripts Healthcare, Amphenol, Meredith, Amicus Therapeutics, Oscient Pharmaceuticals, Acergy S.A., I-Flow

Mon, 21 Jan 2008 14:14:59 GMT

Zacks senior chemical industry analyst Paul Raman, CFA has maintained his Buy rating to Ludwigshafen, Germany-based chemical giant BASF Aktiengesellschaft (BASFY) in his latest report on the company. We excerpted the following details:[More...]

How Goldman Secretly Bet on the Housing Crash

Sun, 01 Nov 2009 17:49:00 GMT

Nov. 1--WASHINGTON -- In 2006 and 2007, Goldman Sachs Group peddled more than $40 billion in securities backed by at least 200,000 risky home mortgages, but never told the buyers it was secretly betting that a sharp drop in U.S. housing prices would send the value of those securities plummeting.
Only later did investors discover that what Goldman had promoted as triple-A rated investments were closer to junk.
Now, pension funds, insurance companies, labor unions and foreign financial institutions that bought those dicey mortgage securities are facing large losses, and a five-month McClatchy investigation has found that Goldman's failure to disclose that it made secret, exotic bets on an imminent housing crash may have violated securities laws.

[More...]

How Goldman Secretly Bet on the Housing Crash

Sun, 01 Nov 2009 07:47:00 GMT

WASHINGTON _ In 2006 and 2007, Goldman Sachs Group peddled more than $40 billion in securities backed by at least 200,000 risky home mortgages, but never told the buyers it was secretly betting that a sharp drop in U.S. housing prices would send the value of those securities plummeting.
Only later did investors discover that what Goldman had promoted as triple-A rated investments were closer to junk.
Now, pension funds, insurance companies, labor unions and foreign financial institutions that bought those dicey mortgage securities are facing large losses, and a five-month McClatchy Newspapers investigation has found that Goldman's failure to disclose that it made secret, exotic bets on an imminent housing crash may have violated securities laws.

[More...]

Cylex, Inc. Appoints Brad L. Stewart As Chief Executive Officer and Chairman of the Board

Thu, 10 Sep 2009 13:53:00 GMT

COLUMBIA, Md., Sept. 10 /PRNewswire/ -- Cylex, Inc., a venture- backed global life sciences company that develops and manufactures research and in vitro diagnostic products intended to illuminate immunity, announced today the appointment of the company's president, Brad L. Stewart, to chief executive officer and chairman of the board.
Since joining Cylex as president in December 2007, Mr. Stewart has successfully led the development of the company's commercial infrastructure, expansion internationally to 18 countries and substantial revenue growth.
"The expanded commercialization of Cylex's technology presents an exciting opportunity for the company to develop cellular diagnostics for diseases and treatments where the immune system is affected," said President, CEO and Chairman Brad L. Stewart.

[More...]

StockPreacher.Com Issues Trading Outlook for Keryx Biopharmaceuticals Inc.

Mon, 10 Aug 2009 11:46:00 GMT

DALLAS, Aug. 10, 2009 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring pharmaceutical company Keryx Biopharmaceuticals Inc. (Nasdaq:KERX).
The investment report on Keryx Biopharmaceuticals Inc. (Nasdaq:KERX) should be of particular interest to other pharmaceutical companies: Baxter International Inc. (NYSE:BAX), Amgen Inc. (Nasdaq:AMGN), Genzyme Corp. (Nasdaq:GENZ) and Amicus Therapeutics Inc. (Nasdaq:FOLD).
It is available at: http://www.stockpreacher.com/n/KERX

[More...]

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

Wed, 05 Aug 2009 19:55:00 GMT

Amicus Therapeutics today announced financial results for the second quarter 2009.[More...]

Amicus Therapeutics Announces Second Quarter 2009 Financial Results Release Date

Wed, 29 Jul 2009 11:56:00 GMT

Amicus Therapeutics will announce second quarter 2009 financial results after the regular close of markets on Wednesday, August 5, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EDT.[More...]

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

Mon, 22 Jun 2009 11:57:00 GMT

- FDA Agreement Reached on Phase 3 Study Design, Primary Endpoint and Histological Methodology -[More...]

Amicus Therapeutics to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference on May 13, 2009

Mon, 11 May 2009 11:57:00 GMT

Amicus Therapeutics today announced that the Company's Chief Operating Officer, Matthew R. Patterson, will be presenting at the upcoming Bank of America and Merrill Lynch Conference in New York City. Mr. Patterson's presentation is scheduled to begin on Wednesday, May 13th at 4:00 p.m. EDT.[More...]

Amicus Therapeutics Announces First Quarter 2009 Financial Results

Thu, 07 May 2009 19:56:00 GMT

Amicus Therapeutics Announces First Quarter 2009 Financial Results[More...]

Amicus Therapeutics Announces First Quarter 2009 Financial Results Release Date

Thu, 30 Apr 2009 11:57:00 GMT

Amicus Therapeutics will announce first quarter 2009 financial results after the regular close of markets on Thursday, May 7, 2009. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EDT.[More...]

Amicus Therapeutics to Present at the 16th Annual Future Leaders in the Biotech Industry Conference

Mon, 30 Mar 2009 11:55:00 GMT

Amicus Therapeutics today announced that the Company's Chief Operating Officer, Matthew R. Patterson, will be presenting at the upcoming 16th Annual Future Leaders in the Biotech Industry conference at New York City's Millennium Broadway Hotel and Conference Center. Mr. Patterson's presentation is scheduled to begin on Thursday, April 2, 2009 at 9:30 a.m. EDT.[More...]